Last updated on September 2017

A Dose Escalation Study Of PF-06801591 In Melanoma Head And Neck Cancer (SCCHN) Ovarian Sarcoma Non-Small Cell Lung Cancer Urothelial Carcinoma or Other Solid Tumors


Brief description of study

Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.

Detailed Study Description

Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety, efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous (SC) in previously treated adult patients with locally advanced or metastatic melanoma, squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell lung carcinoma (NSCLC), urothelial carcinoma or other solid tumors. The first part of the study, Part 1 dose escalation, was designed to assess the safety and tolerability of increasing dose levels of IV or SC administered PF-06801591 to establish the maximum tolerated dose (MTD) using a modified Toxicity Probability Interval (mTPI) design. Part 2 expansion is designed to further evaluate the safety and efficacy of 300 mg of PF-06801591 administered SC once every 4 weeks in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose (RP2D). Part 1 enrollment has completed, enrollment will only be allowed for Part 2.

Clinical Study Identifier: NCT02573259

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Pfizer CT.gov Call Center

Research Administration Office: Clinical Research Unit
Los Angeles, CA United States
  Connect »

Pfizer CT.gov Call Center

Ronald Reagan Medical Center, Department of Radiological Sciences
Los Angeles, CA United States
  Connect »

Pfizer CT.gov Call Center

Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, CA United States
  Connect »

Pfizer CT.gov Call Center

UCLA Hematology & Oncology Clinic
Los Angeles, CA United States
  Connect »

Pfizer CT.gov Call Center

Santa Monica UCLA Hematology & Oncology Clinic
Santa Monica, CA United States
  Connect »

Pfizer CT.gov Call Center

Comprehensive Cancer Centers of Nevada
Las Vegas, NV United States
  Connect »

Pfizer CT.gov Call Center

UNC Cancer Hospital Infusion Pharmacy
Chapel Hill, NC United States
  Connect »

Pfizer CT.gov Call Center

UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, NC United States
  Connect »

Pfizer CT.gov Call Center

Tennessee Oncology, PLLC
Nashville, TN United States
  Connect »

Pfizer CT.gov Call Center

The Sarah Cannon Research Institute
Nashville, TN United States
  Connect »